Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record.

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

Open access
Dass, Shouvik, Rawstron, Andy C., Vital, Edward M., Henshaw, Karen, McGonagle, Dennis, Emery, Paul · 2008 · Arthritis & Rheumatism

Abstract

Objective: In rheumatoid arthritis (RA), B cell depletion occurs in all patients treated with rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was used to test the hypothesis that B cell depletion is variable, and that incomplete depletion leads to a poorer outcome. Methods: Sixty patients with active RA unresponsive to anti–tumor necrosis factor agents received two 1‐gram infusions of rituximab. B cell numbers were measured by highly sensitive flow cytometry before and after each infusion and at 3‐month intervals thereafter. A reduction in B cell levels below 0.0001 × 10 9/liter was defined as complete depletion (compared with 0.05 × 10 9/liter by conventional cytometry). Clinical responses were measured using the European League Against Rheumatism (EULAR) criteria. Results: At 6 months, 92% of patients had a moderate‐to‐good clinical response according to the EULAR criteria. B cells were detected in 63% of patients after the first infusion of rituximab (median level 0.0009 × 10 9/liter [range <0.0001–0.0015 × 10 9/liter), and these patients had poorer clinical outcomes than patients with complete depletion. At 9 months, 82% of patients with complete depletion had a moderate‐to‐ good EULAR response, compared with 43% of those with partial depletion (P = 0.01). At 12 months, 59% of complete responders had a moderate‐to‐good EULAR response, compared with 21% of those with partial depletion (P = 0.01). Patients in whom B cells were depleted only after the second infusion did no better than those in whom depletion was never complete and had poorer clinical outcomes than those in whom depletion was initially complete. Conclusion: This study is the first to show, using a highly sensitive analysis, that rituximab therapy is associated with variable diminution in B cell numbers. A lack of complete depletion of B cells after 1 infusion was associated with a poorer outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23902

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
Dass, S., Rawstron, A. C., Vital, E. M., Henshaw, K., McGonagle, D., & Emery, P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-09-29
Volume
58
Issue
10
Pages
2993-2999
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2004348520
Cited by
210
References
0
FWCI
13.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.23902
The paper
Dass, S., Rawstron, A. C., Vital, E. M., Henshaw, K., McGonagle, D., & Emery, P. (2008). Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.23902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.